Back to all ideas
HealthTech/AI RisingHard to Build

AI-Powered Clinical Trial Matching

AI platform that matches patients to eligible clinical trials by analyzing medical records against trial protocols in real-time

1041 upvotes
Added Mar 1, 2026
AIHealthcareClinical TrialsPharmaNLP
View Full Business Plan

TAM

$640M

Search Volume

2,200/mo

Reddit Mentions

280/mo

YoY Growth

+24.8%

Search & Social Trends

12-month trend of search volume and Reddit mentions

The Problem

Only 5% of adult cancer patients participate in clinical trials, despite 70% expressing willingness. Physicians lack time to review 400,000+ active trials against each patient's eligibility criteria (30+ criteria per trial). Manual screening takes 2 hours per patient per trial. 85% of trials fail to enroll on time. Rural and minority patients are systematically underrepresented.

The Solution

An AI platform that integrates with hospital EHR systems (Epic, Cerner, Meditech) to continuously analyze patient records against trial eligibility criteria using clinical NLP. Alerts treating physicians with pre-screened eligibility summaries and one-click referral workflows. Patient-facing portal for self-screening. Diversity analytics ensure representative enrollment. HIPAA-compliant, IRB-approved architecture.

Executive Summary

The AI clinical trial patient matching market was valued at $640M in 2024, growing at 24.8% CAGR toward $2.4B by 2030. 80% of trials fail enrollment deadlines, adding $600K-$8M per month of delay. Deep 6 AI (acquired by Tempus AI, $6.1B company) uses NLP on unstructured records. Antidote ($28.9M raised, Merck-backed) connects patients via digital channels. TrialSpark ($142M raised) runs its own trial sites. The key challenge is EHR integration (Epic, Cerner) and IRB trust, but unit economics are strong ($1K-5K per enrolled patient).

Competitive Landscape

Deep 6 AI (Tempus)deep6.ai
Acquired by Tempus ($6.1B)

Weakness: Now part of Tempus; may deprioritize standalone trial matching as Tempus focuses on genomics

Antidoteantidote.me
$28.9M

Weakness: Patient-facing digital recruitment only; lacks EHR integration for physician-side matching at point of care

TrialSparktrialspark.com
$142M

Weakness: End-to-end trial operator model (runs own sites); competes with customers rather than serving them

Medidata (Dassault)medidata.com
Acquired ($5.8B)

Weakness: Enterprise clinical data platform; patient matching is a small feature in a massive, expensive suite

Competitor Funding Comparison

Go-to-Market Strategy

Partner with 3-5 academic medical centers for pilot deployments and clinical validation studies

Direct sales to top-20 pharma company clinical operations teams managing largest trial portfolios

Integration with Epic's App Orchard marketplace for distribution to 250+ health systems

Patient advocacy group partnerships (American Cancer Society, NAMI) for patient-side awareness

Key Risks & Challenges

1

EHR integration with Epic and Cerner requires extensive certification, hospital IT approval, and 6-12 month implementation cycles

2

HIPAA compliance and IRB approval processes add regulatory overhead and limit deployment speed

3

Tempus ($6.1B) acquiring Deep 6 AI signals intent to dominate AI-powered clinical trial operations end-to-end

4

Pharma companies are conservative buyers: switching from established CRO relationships requires multi-year trust building

Opportunity Score

48

Critic Viability Score

7

Strong Opportunity

out of 10

Quick Stats

Market Size$640M
Revenue Estimate$60K-$350K
CAC$5,000
Time to MVP16-24 weeks
Revenue ModelPer-patient-matched fee ($200-$2,000) + platform subscription for trial sponsors ($5K-$50K/mo)
CompetitionMedium
Demand Score
73

Target Audience

Pharmaceutical companies and CROs managing clinical trials, academic medical centers with research programs, community oncology practices, patient advocacy organizations